Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Silence Therapeutics (Nasdaq: SLN), a global clinical stage biotechnology company focused on developing precision engineered medicines for disease treatment, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4th at 10:00 a.m. ET. Interested parties can access the live webcast through the Investors section of Silence's website, with an archived replay available after the conference.
Silence Therapeutics (Nasdaq: SLN), un'azienda biotecnologica globale in fase clinica, concentrata nello sviluppo di medicinali ingegnerizzati su misura per il trattamento delle malattie, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. L'azienda parteciperà a una discussione informale mercoledì 4 dicembre alle 10:00 ET. Le parti interessate possono accedere alla diretta streaming tramite la sezione Investitori del sito web di Silence, con una riproduzione archiviata disponibile dopo la conferenza.
Silence Therapeutics (Nasdaq: SLN), una empresa biotecnológica clínica global centrada en el desarrollo de medicamentos de precisión para el tratamiento de enfermedades, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La empresa participará en una charla informal el miércoles 4 de diciembre a las 10:00 a.m. ET. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores del sitio web de Silence, con una repetición archivada disponible después de la conferencia.
Silence Therapeutics (Nasdaq: SLN)는 질병 치료를 위한 정밀 엔지니어링 의약품 개발에 중점을 둔 글로벌 임상 단계 생명공학 회사로, Piper Sandler 제36회 연례 의료 회의에 참석한다고 발표했습니다. 이 회사는 12월 4일 수요일 오전 10시(동부 표준시)에 화상 대화에 참여할 예정입니다. 관심 있는 분들은 Silence 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있으며, 컨퍼런스 후에는 아카이브된 다시 보기 기능이 제공됩니다.
Silence Therapeutics (Nasdaq: SLN), une entreprise de biotechnologie mondiale en phase clinique, spécialisée dans le développement de médicaments sur mesure pour le traitement des maladies, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. L'entreprise participera à une discussion informelle le mercredi 4 décembre à 10h00 ET. Les parties intéressées peuvent accéder au webinaire en direct via la section Investisseurs du site Web de Silence, avec une rediffusion archivées disponible après la conférence.
Silence Therapeutics (Nasdaq: SLN), ein global tätiges biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von präzisionsgefertigten Arzneimitteln zur Behandlung von Krankheiten konzentriert, hat seine Teilnahme an der 36. Jahrestagung im Gesundheitswesen von Piper Sandler bekannt gegeben. Das Unternehmen wird am Mittwoch, dem 4. Dezember, um 10:00 Uhr ET an einem informellen Gespräch teilnehmen. Interessierte können die Live-Übertragung über den Bereich Investoren auf der Website von Silence abrufen, wobei eine aufgezeichnete Wiederholung nach der Konferenz verfügbar sein wird.
- None.
- None.
The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.
About Silence Therapeutics
Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126552153/en/
Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Source: Silence Therapeutics plc
FAQ
When is Silence Therapeutics (SLN) presenting at the Piper Sandler Healthcare Conference?
How can investors watch Silence Therapeutics' (SLN) Piper Sandler Conference presentation?
What type of event will Silence Therapeutics (SLN) participate in at the Piper Sandler Conference?
